IP Library Granted Patent US 12,508,365
Granted Patent B2
US 12,508,365 · App. 18/896,045 · Granted Dec 30, 2025

Site tracking based on connectivity in infusion pump systems

Inventors: Josh Juster (San Diego, CA); Geoffrey Kruse (San Diego, CA)
Assignee: TANDEM DIABETES CARE, INC.
A61M5/1723A61B5/14532A61M2205/3553A61M2205/502
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,508,365
App. No.
18/896,045
Granted
Dec 30, 2025
Kind
B2
Abstract

Enclosed herein are methods and systems for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system, and a smartphone or other multi-purpose consumer electronic device (i.e., remote control device). Communications among these devices can be coordinated to ensure reliable and consistent transmission of medical data.

Claims (27)

1 . A method of coordinating wireless communications in an infusion pump system including a continuous glucose monitoring (CGM) device and an infusion pump, comprising:

initiating a communication session between the infusion pump and the CGM device;

determining that the infusion pump is communicatively coupled to the CGM device;

determining a first location of the infusion pump relative to a body of a user;

determining a first location of the CGM device relative to the body of the user;

determining a measurement of communication signal quality between the infusion pump and the CGM device as a function of a relative positioning of the first location of the infusion pump and the first location of the CGM device with respect to the body of the user.

2 . The method of claim 1 , further comprising recording the measurement of communication signal quality in a memory.

3 . The method of claim 1 , further comprising displaying on a user interface an indication of communication signal quality at one or more other locations of the infusion pump and/or one or more other locations of the CGM device relative to the body of the user.

4 . The method of claim 3 , wherein displaying an indication of communication signal quality at one or more other locations of the infusion pump and/or one or more other locations of the CGM device relative to the body of the user includes displaying an indication of communication signal quality at one or more other locations of the infusion pump relative to the first location of the CGM device.

5 . The method of claim 3 , wherein displaying an indication of communication signal quality at one or more other locations of the infusion pump and/or one or more other locations of the CGM device relative to the body of the user includes displaying an indication of communication signal quality at one or more other locations of the CGM device relative to the first location of the infusion pump.

6 . The method of claim 3 , wherein displaying an indication of communication signal quality at one or more other locations of the infusion pump and/or one or more other locations of the CGM device relative to the body of the user includes displaying on the user interface a graphical representation of the body of the user identifying the one or more locations.

7 . The method of claim 3 , wherein the indication of communication signal quality at one or more other locations of the infusion pump and/or one or more other locations of the CGM device relative to the body of the user is displayed if the measurement of communication signal quality between the infusion pump and the CGM device based on the first location of the infusion pump and the first location of the CGM device relative to the body of the user is below a predetermined threshold.

8 . The method of claim 1 , further comprising comparing the measurement of communication signal quality between the infusion pump and the CGM device based on a first location of the infusion pump and a first location of the CGM device relative to the body of the user to a predetermined threshold.

9 . The method of claim 8 , further comprising providing a recommendation to move at least one of the infusion pump and the CGM device to a second location if the measurement of communication signal quality is below the predetermined threshold.

10 . The method of claim 7 , further comprising displaying an indication that the measurement of communication signal quality is acceptable on the user interface if the measurement of communication signal quality is above the predetermined threshold.

11 . A method of coordinating wireless communications in an infusion pump system including a continuous glucose monitoring (CGM) device and an infusion pump, comprising:

receiving input through a user interface from a user initiating a communication session between the infusion pump and the CGM device; and

providing guidance on the user interface to the user on where to position at least one of the infusion pump and the CGM device relative to a body of the user based on a measure of signal strength between the infusion pump and the CGM device based on a relative position of the infusion pump and the CGM device with respect to the body of the user.

12 . The method of claim 11 , wherein providing guidance on where to position at least one of the infusion pump and the CGM device relative to the body of the user includes displaying a graphical representation of the body of the user on the user interface.

13 . The method of claim 12 , where providing guidance on where to position at least one of the infusion pump and the CGM device includes displaying a measurement of communication signal quality between the infusion pump and the CGM device at one or more previous locations of the infusion pump and CGM device on the graphical representation of the body of the user.

14 . The method of claim 12 , where providing guidance on where to position at least one of the infusion pump and the CGM device includes displaying a measurement of communication signal quality between the infusion pump and the CGM device at a current location of the infusion pump and a current location of the CGM device relative to the body of the user on the graphical representation of the user's body.

15 . The method of claim 14 , further comprising updating the measurement of communication signal quality between the infusion pump and the CGM device on the graphical representation of the body of the user in real-time when the infusion pump or the CGM device is moved from the current location.

16 . The method of claim 11 , providing guidance on the user interface to the user on where to position at least one of the infusion pump and the CGM device relative to the body of the user based on a measure of signal strength between the infusion pump and the CGM device includes providing a recommendation for a location for one or more of the infusion pump and the CGM device relative to the body of the user.

17 . The method of claim 16 , wherein providing a recommendation for a location for one or more of the infusion pump and the CGM device relative to the body of the user based on a measure of signal strength between the infusion pump and the CGM device includes providing a recommendation for a location of the CGM device based on a current location of the infusion pump.

18 . The method of claim 16 , wherein providing a recommendation for a location for one or more of the infusion pump and the CGM device relative to the body of the user includes providing a recommendation for a location of the infusion pump based on a current location of the CGM device.

19 . The method of claim 18 , wherein providing a recommendation for a location of the infusion pump is further based on a predicted efficacy of insulin absorption at the location.

20 . The method of claim 11 , wherein providing guidance on the user interface to the user on where to position at least one of the infusion pump and the CGM device relative to the body of the user based on a measure of signal strength between the infusion pump and the CGM device includes providing a color coded indications of areas of different signal strength with different colors.

Continuity (3)
Provisional Application 63604003 · Nov 29, 2023
Provisional Application 63585086 · Sep 25, 2023
Related Publication 20250099679A1 · Mar 27, 2025
References Cited (46)
US 7653425B2 · Hayter et al. · 2010 [cited by applicant]
US 7920907B2 · McGarraugh et al. · 2011 [cited by applicant]
US 7928850B2 · Hayter et al. · 2011 [cited by applicant]
US 7996158B2 · Hayter et al. · 2011 [cited by applicant]
US 8121857B2 · Galasso et al. · 2012 [cited by applicant]
US 8344847B2 · Moberg et al. · 2013 [cited by applicant]
US 8456301B2 · Fennell et al. · 2013 [cited by applicant]
US 8461985B2 · Fennell et al. · 2013 [cited by applicant]
US 9089305B2 · Hovorka · 2015 [cited by applicant]
US 9421324B2 · Sloan · 2016 [cited by applicant]
US 9549324B2 · Birtwhistle et al. · 2017 [cited by applicant]
US 10492141B2 · Kruse · 2019 [cited by applicant]
US 10588575B2 · Gottlieb et al. · 2020 [cited by applicant]
US 10736037B2 · Kruse et al. · 2020 [cited by applicant]
US 20070255348A1 · Holtzclaw · 2007 [cited by applicant]
US 20080004601A1 · Jennewine et al. · 2008 [cited by applicant]
US 20090164239A1 · Hayter et al. · 2009 [cited by applicant]
US 20100185175A1 · Kamen et al. · 2010 [cited by applicant]
US 20100295686A1 · Sloan et al. · 2010 [cited by applicant]
US 20100298685A1 · Hayter et al. · 2010 [cited by applicant]
US 20110009725A1 · Hill et al. · 2011 [cited by applicant]
US 20110044333A1 · Sicurello et al. · 2011 [cited by applicant]
US 20110053121A1 · Heaton · 2011 [cited by applicant]
US 20110098548A1 · Budiman et al. · 2011 [cited by applicant]
US 20110130746A1 · Budiman · 2011 [cited by applicant]
US 20110149759A1 · Jollota · 2011 [cited by applicant]
US 20110152970A1 · Jollota et al. · 2011 [cited by applicant]
US 20130060105A1 · Shah et al. · 2013 [cited by applicant]
US 20140012511A1 · Mensinger et al. · 2014 [cited by applicant]
US 20140180203A1 · Budiman et al. · 2014 [cited by applicant]
US 20140187890A1 · Mensinger et al. · 2014 [cited by applicant]
US 20150273147A1 · Duke et al. · 2015 [cited by applicant]
US 20150289823A1 · Rack-Gomer et al. · 2015 [cited by applicant]
US 20150352282A1 · Mazlish · 2015 [cited by applicant]
US 20160098848A1 · Zamanakos et al. · 2016 [cited by applicant]
US 20160328991A1 · Simpson et al. · 2016 [cited by applicant]
US 20180042559A1 · Cabrera, Jr. et al. · 2018 [cited by applicant]
US 20200206420A1 · Michaud · 2020 [cited by applicant]
US 20200372995A1 · Kruse et al. · 2020 [cited by applicant]
US 20210113766A1 · Kearns et al. · 2021 [cited by applicant]
US 20210128831A1 · Zade · 2021 [cited by examiner]
US 20230034408A1 · Nichols et al. · 2023 [cited by applicant]
US 20250099674A1 · Kruse et al. · 2025 [cited by applicant]
US 20250108162A1 · Kruse et al. · 2025 [cited by applicant]
WO 2017124099A1 · 2017 [cited by applicant]
International Search Report and Written Opinion, Application No. PCT/US2024/048441, dated Dec. 31, 2024. [cited by applicant]